Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 1998, for Celsion Corporation (Note: The request metadata listed "Imunon, Inc.", but the filing text explicitly identifies the registrant as Celsion Corporation). The company is a clinical-stage biotechnology firm focused on developing minimally invasive thermotherapy devices for cancer and benign prostatic hyperplasia (BPH). The company has ceased active sales of current equipment to concentrate resources on developing new technologies, specifically adaptive phase array (APA) technology licensed from MIT and balloon catheter technology.
Key Financial Metrics
| Metric | Q3 1998 (Three Months Ended Dec 31) | Q3 1997 (Three Months Ended Dec 31) |
|---|---|---|
| Total Revenue | $0 | $0 |
| Net Loss | $(547,993) | $(857,172) |
| Loss Per Share (Basic) | $(0.014) | $(0.028) |
| Operating Expenses | $524,679 | $827,902 |
| Cash and Cash Equivalents (Ending) | $100,114 | $32,611 |
| Accumulated Deficit | $(20,012,005) | N/A |
| Total Liabilities | $2,328,280 | N/A |
| Stockholders' Deficit | $(1,991,461) | N/A |
Material Changes vs. Prior Period
- Revenue: Remained at zero as the company ceased active sales to focus on R&D.
- Net Loss: Improved significantly to $(547,993) from $(857,172) in the prior year quarter, primarily due to a reduction in Selling, General, and Administrative (SG&A) expenses.
- SG&A Expenses: Decreased to $357,577 from $725,058. The prior year included $234,375 in compensation expenses for stock issued to the President.
- R&D Expenses: Increased to $167,101 from $102,844 due to increased emphasis on technology enhancements.
- Liquidity: Cash balances increased from $54,920 at the start of the quarter to $100,114 at period end, driven by net cash provided by financing activities ($352,419) which offset operating cash outflows ($307,226).
- Debt: The company repaid notes payable, reducing interest expense to $23,314 from $35,525.
Guidance, Outlook, and Risks
- Capital Adequacy: Management states that existing capital resources are not adequate to fund operations for the next twelve months. The company is dependent on raising additional capital.
- Recent Financing: A $1 million private placement was completed on February 3, 1999, intended to fund Phase I clinical trials for BPH and Breast Cancer Treatment Systems.
- Outlook: Revenue is not expected until new technologies are developed and approved by regulatory agencies. Operating losses are expected to continue during the development phase.
- Risks: If adequate funds are not available, the company may be forced to delay, scale back, or eliminate operations, or relinquish rights to technologies. There is no assurance that additional funding will be available on acceptable terms.
- Legal Proceedings: The company won a countersuit against Eastwell Management Services, Ltd., resulting in a $100,000 judgment in its favor, though Eastwell has filed an appeal.
Investor Verification Checklist
- Verify the status of the $100,000 judgment against Eastwell Management Services and the likelihood of collection given the pending appeal.
- Confirm the utilization of the $1 million raised in the February 1999 private placement and its sufficiency to reach the next funding milestone.
- Monitor the progress of FDA regulatory approvals for the APA and balloon catheter technologies, as these are prerequisites for revenue generation.
- Review the company's burn rate against the current cash balance of ~$100,000 to assess immediate liquidity risk.
- Check for any new equity issuances or debt financings required to bridge the gap before commercialization.